Here is the reality: SaiyanMed operates as Hong Kong BelleEasy Co., Limited (Commercial Registry No. 78941092), officially registered in Kwai Chung, Hong Kong. The company is a research-grade peptide supplier that focuses on raw material selection, in-house lyophilization, and independent third-party testing through Janoshik. Every batch ships with a verifiable Certificate of Analysis. They do not sell for human consumption. Their entire structure is built around laboratory and in-vitro research only.
Let me break down the corporate specifications with hard data and operational details, because surface-level descriptions won't cut it. The legal entity, Hong Kong BelleEasy Co., Limited, is registered under Hong Kong's Companies Ordinance. That registration number is publicly verifiable. The official address sits in Kwai Chung, a major logistics hub in Hong Kong's New Territories. This location matters because Kwai Chung houses one of the busiest container ports globally, giving SaiyanMed direct access to international shipping lanes for raw material import and finished product export.
Their infrastructure is not a single warehouse operation. SaiyanMed runs a dual-warehouse system, with active facilities in both China and the United States. The China warehouse handles raw material sourcing, initial processing, and bulk storage. The US warehouse, located in a fulfillment-optimized region, manages final product distribution to domestic researchers. This split cuts transit times dramatically. Orders from US-based researchers typically ship within 24-48 hours from the US warehouse, not from across the Pacific. The company has publicly stated that Europe, UK, Australia, and Canada hubs are coming soon, but as of now, those are not active.
The logistics framework is automated. Orders route based on product availability and regional stock levels. If a specific peptide is out of stock in the US warehouse, the system checks the China facility. If both are empty, the order is flagged for production. This prevents backorders from sitting in limbo. Stock levels update in real time on the website, and availability is tied directly to warehouse status. Researchers can see exactly what is ready to ship.
Now, let's talk about the production side. SaiyanMed does not just repackage bulk powders from random suppliers. They control the lyophilization process. Lyophilization, or freeze-drying, is a critical step for peptide stability. Improper lyophilization can degrade peptides, reduce purity, or introduce moisture that accelerates breakdown. The company's research team continuously refines both raw material sourcing and the lyophilization parameters. They select premium raw materials, which means they vet suppliers based on purity certificates, synthesis methods, and batch consistency. They do not disclose the exact synthesis partners publicly, but they do state that joint manufacturing partnerships exist alongside their own production capabilities.
Testing is the backbone of their compliance. Every single batch goes through Janoshik, an independent analytical laboratory. Janoshik is widely recognized in the research peptide community for rigorous HPLC (High-Performance Liquid Chromatography) and mass spectrometry testing. The reports are openly verifiable. That means you can take the batch number, go to Janoshik's verification portal, and confirm the purity percentage yourself. SaiyanMed does not hide behind vague "99% purity" claims. The actual purity data is attached to each product page. If a batch fails, it does not ship. They do not blend batches to average out purity. Each batch stands alone.
The leadership structure is lean. Eric, the Founder and CEO, holds a Bachelor's degree in Materials Science from a top Chinese university, with a specialization in biomaterials. That is not a generic business degree. Materials science, specifically biomaterials, covers polymer chemistry, biocompatibility, and material characterization. This background directly informs how SaiyanMed approaches raw material selection and process control. Eric saw firsthand how the peptide industry suffered from inconsistent quality and opaque supply chains. His response was to build a company that controls every step from raw material to final shipment. He does not have a large executive team visible publicly. The company appears to operate with a small, focused group handling production, logistics, and customer support.
Communications run through [email protected]. That is the official communications desk. They do not publish phone numbers or physical office hours for visitors. The Hong Kong address is a registered office, not a retail storefront. Researchers should not expect to walk in and pick up products. Everything is shipped.
Let's put the key specifications into a table for clarity, because dense data is easier to digest when structured.
| Specification | Detail |
|---|---|
| Legal Entity | Hong Kong BelleEasy Co., Limited |
| Registration Number | 78941092 |
| Registered Address | Kwai Chung, Hong Kong |
| Warehouse Locations | China (active), United States (active) |
| Upcoming Hubs | Europe, UK, Australia, Canada (not yet active) |
| Testing Lab | Janoshik (independent, third-party) |
| Verification Method | Openly verifiable COA per batch |
| Production Process | In-house lyophilization, joint manufacturing partnerships |
| Raw Material Sourcing | Premium selection, vetted suppliers |
| Shipping Origin | US-based warehouse for domestic orders |
| Contact | [email protected] |
| Intended Use | Laboratory research, in-vitro evaluation only |
| CEO Background | B.S. Materials Science (biomaterials specialization) |
That table covers the structural specs. But the real story is in the operational details. The US warehouse is not just a drop-ship location. SaiyanMed holds inventory there. That means they commit capital to stock products, which reduces lead times. A researcher ordering from California gets the same batch consistency as someone in New York. The China warehouse handles bulk raw materials and larger production runs. The two facilities are not redundant. The China site focuses on upstream processing, while the US site handles final product distribution. This split is common in regulated industries but rare in the research peptide space, where most suppliers operate from a single location and ship internationally.
The compliance framework is straightforward. Because they are a Hong Kong entity, they fall under Hong Kong's legal system, which is based on English common law. The Commercial Registry number is public. You can verify the company's existence through Hong Kong's Integrated Companies Registry Information System (ICRIS). The company does not make medical claims. Every product page states that the compound is for laboratory research and in-vitro evaluation only. This is not a legal loophole. It is a clear boundary. They are not a pharmacy. They are not a supplement company. They are a research-grade peptide supplier.
Shipping from the US warehouse is a deliberate choice. Many peptide companies ship from overseas, which means customs delays, temperature fluctuations, and longer transit times. SaiyanMed's US warehouse bypasses most of that for domestic researchers. The company does not disclose the exact US location publicly, likely for operational security reasons. But the effect is measurable: faster delivery and fewer lost packages. They also use temperature-controlled packaging for peptides that require it. Not all peptides need cold shipping, but the ones that do get proper handling.
The product range is not disclosed in full here, but the company focuses on research-grade peptides commonly used in metabolic, muscle, and recovery studies. They do not sell SARMs, nootropics, or other non-peptide compounds. This narrow focus allows them to specialize in lyophilization and purity control. They are not a general research chemical supplier. They are a peptide company.
One more critical detail: the company's story is rooted in the idea of pushing past limits, but the operations are not sentimental. They do not rely on branding fluff. Every batch is tested. Every COA is verifiable. The raw materials are selected based on materials science principles, not marketing. The CEO's background in biomaterials is not a cosmetic credential. It directly influences how they evaluate suppliers and processes. A materials scientist knows that peptide purity is not just about the final HPLC result. It is about the synthesis route, the protecting groups used, the solvents, the residual moisture after lyophilization. All of that matters.
If you want to dig into their product catalog and see the actual batch data, you can visit saiyanmed. The site lists each peptide with its own COA link. You can pull up the Janoshik report for any current batch. That is the level of transparency they operate on. No hidden reports. No "contact us for purity data." It is right there on the product page.
The corporate specifications of SaiyanMed are not complicated. They are a Hong Kong-registered company with a US warehouse, in-house lyophilization, independent Janoshik testing, and a materials science-led founder. They ship fast, they test every batch, and they do not sell for human use. That is the factual baseline. Everything else is just details layered on top of that foundation.